WST WEST PHARMACEUTICAL SERVICES INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 105770 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.6%
TTM net income YoY29.9%
TTM EPS YoY32.0%
Revenue 3-yr CAGR5.1%
Net income 3-yr CAGR4.5%
Margins
Gross margin37.6%
Operating margin23.0%
Net margin18.8%
FCF margin13.3%
EBITDA margin28.4%
Returns
ROE21.2%
ROA15.6%
ROIC (approx.)23.0%
Asset turnover0.83x
Leverage & solvency
Liabilities / assets26.9%
Debt / equity0.07x
Current ratio2.82x
Interest coverage96.32x
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio-0.4%
Payout ratio9.8%
Capex / revenue5.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B |
| Cost of revenue | $1.97B | $1.89B | $1.82B | $1.75B | $1.66B |
| Gross profit | $1.10B | $998.50M | $1.13B | $1.14B | $1.18B |
| R&D expense | $74.30M | $69.10M | $68.40M | $58.50M | $52.80M |
| SG&A expense | $393.60M | $338.50M | $353.40M | $316.90M | $362.80M |
| Operating income | $584.90M | $569.90M | $676.00M | $734.00M | $752.30M |
| Interest expense | $500,000 | $3.00M | $9.00M | $7.90M | $8.20M |
| Pretax income | $600.90M | $585.50M | $698.00M | $679.90M | $748.90M |
| Income tax | $121.60M | $107.50M | $122.30M | $114.70M | $107.20M |
| Net income | $493.70M | $492.70M | $593.40M | $585.90M | $661.80M |
| EBITDA | $756.30M | $725.30M | $813.30M | $854.60M | $874.60M |
| EPS (basic) | 6.83 | 6.75 | 7.98 | 7.87 | 8.89 |
| EPS (diluted) | 6.79 | 6.69 | 7.88 | 7.73 | 8.67 |
| Dividends declared per share | 0.86 | 0.82 | 0.78 | 0.74 | 0.70 |
| Weighted avg. shares (diluted) | 72.70M | 73.70M | 75.30M | 75.80M | 76.30M |
| Balance sheet | |||||
| Cash & equivalents | $791.30M | $484.60M | $853.90M | $894.30M | $762.60M |
| Receivables | $574.40M | $552.50M | $512.00M | $507.40M | $489.00M |
| Inventory | $443.90M | $377.00M | $434.70M | $414.80M | $378.40M |
| Current assets | $1.98B | $1.54B | $1.94B | $1.92B | $1.74B |
| PP&E, net | $1.73B | $1.58B | $1.41B | $1.16B | $1.06B |
| Goodwill | $109.90M | $106.00M | $108.50M | $107.30M | $109.90M |
| Intangibles | $7.70M | $10.80M | $15.10M | $18.40M | $23.00M |
| Total assets | $4.27B | $3.64B | $3.83B | $3.62B | $3.31B |
| Current liabilities | $654.90M | $550.40M | $671.80M | $519.00M | $594.10M |
| Short-term debt | $0 | $0 | $134.00M | $2.20M | $44.20M |
| Long-term debt | $202.80M | $202.60M | $72.80M | $206.70M | $208.80M |
| Total debt | $202.80M | $202.60M | $206.80M | $208.90M | $253.00M |
| Total liabilities | $1.09B | $961.10M | $948.50M | $931.90M | $978.40M |
| Shareholders' equity | $3.18B | $2.68B | $2.88B | $2.68B | $2.34B |
| Net debt | -$588.50M | -$282.00M | -$647.10M | -$685.40M | -$509.60M |
| Shares outstanding | 72.00M | 72.30M | 73.50M | 74.10M | 74.20M |
| Cash flow statement | |||||
| Operating cash flow | $754.80M | $653.40M | $776.50M | $724.00M | $584.00M |
| Capital expenditure | $285.90M | $377.00M | $362.00M | $284.60M | $253.40M |
| Free cash flow | $468.90M | $276.40M | $414.50M | $439.40M | $330.60M |
| Investing cash flow | -$285.90M | -$378.70M | -$368.70M | -$288.20M | -$253.10M |
| Financing cash flow | -$185.10M | -$622.60M | -$459.60M | -$293.60M | -$168.10M |
| Depreciation & amortization | $171.40M | $155.40M | $137.30M | $120.60M | $122.30M |
| Stock-based compensation | $23.80M | $18.70M | $23.30M | $23.70M | $37.50M |
| Dividends paid | $61.20M | $59.10M | $57.00M | $54.10M | $51.10M |
| Share buybacks | $134.00M | $560.90M | $438.30M | $202.80M | $137.10M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.